- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Some tried-and-true indicators show what's really going on with the market.
Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.